Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.

ABSTRACT: In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no longer available. Prognosis and survival of patients with NETs are determined by the location of the primary lesion, biochemical functional status, differentiation, initial staging, and response to treatment. Somatostatin analogue (SSA) therapy has been a mainstay of antisecretory therapy in functioning neuroendocrine tumors, which cause various clinical symptoms depending on hormonal hypersecretion. Beyond symptomatic management, recent research demonstrates that SSAs exert antiproliferative effects and inhibit tumor growth via the somatosta

SUBMITTER: Stueven AK 

PROVIDER: S-EPMC6627451 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature